UY27961A1 - Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas - Google Patents
Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinasInfo
- Publication number
- UY27961A1 UY27961A1 UY27961A UY27961A UY27961A1 UY 27961 A1 UY27961 A1 UY 27961A1 UY 27961 A UY27961 A UY 27961A UY 27961 A UY27961 A UY 27961A UY 27961 A1 UY27961 A1 UY 27961A1
- Authority
- UY
- Uruguay
- Prior art keywords
- triazolo
- trifluoro
- inflammatory compounds
- piridinas
- oxazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas. Nuevas triazolo-piridinas de fórmula con la condición de que dicho compuesto de fórmula I ni puede ser 6-(4-(2,4-Difluoro- fenil)-oxazol-5-il)-3-isopropil-(1,2,4)triazolo(4,3-a)piridina;o 6-(4-(3,4-Difluoro-fenil)-oxazol-5-il)-3-isopropil-(1,2,4)triazolo(4,3-a)piridina; Intermedios para su preparación, composiciones farmacéuticas que los contienen y a su uso médico. Los compuestos de la presente invención son potentes inhibidores de quinasas MAP, preferiblemente de l quinasa p38. Son útiles en el tratamiento de la inflamación, osteoartritis, artritis reumatoide, cáncer, reperfusión o isquemia en apoplejía, enfermedades autoinmunes y otros trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40717702P | 2002-08-30 | 2002-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27961A1 true UY27961A1 (es) | 2004-03-31 |
Family
ID=31978432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27961A UY27961A1 (es) | 2002-08-30 | 2003-08-29 | Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas |
Country Status (17)
Country | Link |
---|---|
US (1) | US7259171B2 (es) |
EP (1) | EP1537108B1 (es) |
JP (1) | JP2006504680A (es) |
AR (1) | AR041078A1 (es) |
AT (1) | ATE414705T1 (es) |
AU (1) | AU2003259438A1 (es) |
BR (1) | BR0313965A (es) |
CA (1) | CA2494754A1 (es) |
DE (1) | DE60324806D1 (es) |
ES (1) | ES2315560T3 (es) |
GT (1) | GT200300187A (es) |
MX (1) | MXPA05002304A (es) |
PA (1) | PA8579601A1 (es) |
PE (1) | PE20040978A1 (es) |
TW (1) | TW200420562A (es) |
UY (1) | UY27961A1 (es) |
WO (1) | WO2004020440A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072072A1 (en) * | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
JP2008509985A (ja) * | 2004-08-18 | 2008-04-03 | ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー | 炎症治療用の新規トリアゾロピリジン化合物 |
ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
ES2377821T3 (es) * | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
RS56410B1 (sr) * | 2009-07-27 | 2018-01-31 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
JP5934787B2 (ja) | 2011-05-10 | 2016-06-15 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
EP2875014B1 (en) | 2012-07-17 | 2017-11-29 | Washington University | Anti-mucus drugs and uses therefor |
EP3521284B1 (en) | 2013-03-15 | 2020-12-02 | The Trustees of Columbia University in the City of New York | Pyrazine compounds as map kinase modulators and uses thereof |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN109867617A (zh) * | 2019-04-03 | 2019-06-11 | 南京格亚医药科技有限公司 | 一种4-甲氧基吡咯中间体的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716972A (en) * | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
ES2140561T3 (es) * | 1993-09-17 | 2000-03-01 | Smithkline Beecham Corp | Proteina de union de farmacos. |
JPH09505055A (ja) * | 1993-11-08 | 1997-05-20 | スミスクライン・ビーチャム・コーポレイション | サイトカイン媒介疾患治療用オキサゾール |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
CZ216498A3 (cs) * | 1996-01-11 | 1999-08-11 | Smithkline Beecham Corporation | Nové substituované imidazolové sloučeniny |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
WO1999061440A1 (en) | 1998-05-26 | 1999-12-02 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
JP4634613B2 (ja) | 1998-12-16 | 2011-02-16 | アベンティス・フアーマ・リミテッド | ヘテロアリール環状アセタール類 |
US6469018B1 (en) | 1999-01-08 | 2002-10-22 | Smithkline Beecham Corporation | Compounds |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
CZ20032185A3 (en) * | 2001-03-09 | 2004-06-16 | Pfizer Products Inc. | Triazolopyridines as anti-inflammatory agents |
AP2002002460A0 (en) | 2001-03-09 | 2002-06-30 | Pfizer Prod Inc | Novel benzimidazole anti-inflammatory compounds. |
ES2247271T3 (es) | 2001-04-04 | 2006-03-01 | Pfizer Products Inc. | Nuevos benzotriazoles como compuestos antiinflamatorios. |
-
2003
- 2003-08-05 PA PA20038579601A patent/PA8579601A1/es unknown
- 2003-08-19 WO PCT/IB2003/003847 patent/WO2004020440A1/en active Application Filing
- 2003-08-19 EP EP03791145A patent/EP1537108B1/en not_active Expired - Lifetime
- 2003-08-19 ES ES03791145T patent/ES2315560T3/es not_active Expired - Lifetime
- 2003-08-19 MX MXPA05002304A patent/MXPA05002304A/es active IP Right Grant
- 2003-08-19 AT AT03791145T patent/ATE414705T1/de not_active IP Right Cessation
- 2003-08-19 JP JP2004532622A patent/JP2006504680A/ja not_active Withdrawn
- 2003-08-19 AU AU2003259438A patent/AU2003259438A1/en not_active Abandoned
- 2003-08-19 CA CA002494754A patent/CA2494754A1/en not_active Abandoned
- 2003-08-19 DE DE60324806T patent/DE60324806D1/de not_active Expired - Lifetime
- 2003-08-19 BR BR0313965-4A patent/BR0313965A/pt not_active IP Right Cessation
- 2003-08-25 PE PE2003000863A patent/PE20040978A1/es not_active Application Discontinuation
- 2003-08-27 US US10/649,236 patent/US7259171B2/en not_active Expired - Fee Related
- 2003-08-28 AR ARP030103118A patent/AR041078A1/es unknown
- 2003-08-29 UY UY27961A patent/UY27961A1/es not_active Application Discontinuation
- 2003-08-29 GT GT200300187A patent/GT200300187A/es unknown
- 2003-08-29 TW TW092123952A patent/TW200420562A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2494754A1 (en) | 2004-03-11 |
PE20040978A1 (es) | 2004-12-28 |
US20040053958A1 (en) | 2004-03-18 |
EP1537108A1 (en) | 2005-06-08 |
DE60324806D1 (de) | 2009-01-02 |
TW200420562A (en) | 2004-10-16 |
AU2003259438A1 (en) | 2004-03-19 |
JP2006504680A (ja) | 2006-02-09 |
EP1537108B1 (en) | 2008-11-19 |
MXPA05002304A (es) | 2005-06-08 |
AR041078A1 (es) | 2005-04-27 |
BR0313965A (pt) | 2005-07-19 |
PA8579601A1 (es) | 2004-05-07 |
WO2004020440A1 (en) | 2004-03-11 |
GT200300187A (es) | 2004-06-23 |
ATE414705T1 (de) | 2008-12-15 |
ES2315560T3 (es) | 2009-04-01 |
US7259171B2 (en) | 2007-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27961A1 (es) | Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas | |
UY27199A1 (es) | Nuevos compuestos antiinflamatorios de triazolopiridinas | |
CY1121021T1 (el) | Ιμιδαζοτριαζινες και ιμιδαζοπυριμιδινες ως αναστολεις κινασης | |
PA8596901A1 (es) | Inhibidores de p38 y metodos de uso de ellos | |
UY27535A1 (es) | Benzamida , heteroarilamida y amidas inversas, | |
AR048912A1 (es) | Inmunoglobulinas anti-nogo | |
PA8601701A1 (es) | Compuestos farmacéuticos novedosos | |
CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
CL2008001230A1 (es) | Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. | |
AR048069A1 (es) | Derivados de pirazolo con heteroarilo fusionado | |
ECSP099662A (es) | Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
CL2007001996A1 (es) | Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
CL2011002956A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos. | |
ES2191187T3 (es) | Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa. | |
PA8593001A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
UY28214A1 (es) | Nuevos compuestos heteroaromáticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
CL2011001215A1 (es) | Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes. | |
UY29838A1 (es) | Derivados sustituidos de 4,5,6,7-tetrahidropirrolo(3,2,c)piridin-4-ona y de 4,5-tetrahidropirrolo(3,2,c)piridin-4-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones | |
UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
GB0107901D0 (en) | Anti-cancer compounds | |
AR048501A1 (es) | Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla | |
CY1110666T1 (el) | Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων | |
UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150506 |